Clinical Trial Update: Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L) [Phase 2]

View source ↗

Summary

An update on a Phase 2 trial evaluating the safety of dose escalation in definitive hypofractionated radiation therapy using the SPACEOAR device for localized, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Samsung Medical Center | Conditions: Low-to-intermediate-risk Prostate Carcinoma | Phase 2 | Status: RECRUITING